274 related articles for article (PubMed ID: 26402390)
21. Sources of prescription opioids among diagnosed opioid abusers.
Shei A; Rice JB; Kirson NY; Bodnar K; Birnbaum HG; Holly P; Ben-Joseph R
Curr Med Res Opin; 2015 Apr; 31(4):779-84. PubMed ID: 25661018
[TBL] [Abstract][Full Text] [Related]
22. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013.
Florence CS; Zhou C; Luo F; Xu L
Med Care; 2016 Oct; 54(10):901-6. PubMed ID: 27623005
[TBL] [Abstract][Full Text] [Related]
23. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis.
Feldman SR; Zhao Y; Shi L; Tran MH
J Manag Care Spec Pharm; 2015 Oct; 21(10):874-88. PubMed ID: 26402388
[TBL] [Abstract][Full Text] [Related]
24. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
25. The economic burden of diagnosed opioid abuse among commercially insured individuals.
Rice JB; Kirson NY; Shei A; Enloe CJ; Cummings AK; Birnbaum HG; Holly P; Ben-Joseph R
Postgrad Med; 2014 Jul; 126(4):53-8. PubMed ID: 25141243
[TBL] [Abstract][Full Text] [Related]
26. The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients.
Pergolizzi JV; Ma L; Foster DR; Overholser BR; Sowinski KM; Taylor R; Summers KH
J Manag Care Spec Pharm; 2014 May; 20(5):467-76. PubMed ID: 24761818
[TBL] [Abstract][Full Text] [Related]
27. Empirical view of opioid dependence.
Ruetsch C
J Manag Care Pharm; 2010 Feb; 16(1 Suppl B):S9-13. PubMed ID: 20146549
[TBL] [Abstract][Full Text] [Related]
28. Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
[TBL] [Abstract][Full Text] [Related]
29. A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets.
Rubino M; Summers KH; Puenpatom A; Fu C; Ohsfeldt RL; Ben-Joseph RH
J Manag Care Pharm; 2011 Jun; 17(5):367-76. PubMed ID: 21657806
[TBL] [Abstract][Full Text] [Related]
30. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
[TBL] [Abstract][Full Text] [Related]
31. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of diagnosed opioid abuse and its economic burden in the veterans health administration.
Baser O; Xie L; Mardekian J; Schaaf D; Wang L; Joshi AV
Pain Pract; 2014 Jun; 14(5):437-45. PubMed ID: 23809020
[TBL] [Abstract][Full Text] [Related]
33. Costs of opioid abuse and misuse determined from a Medicaid database.
McAdam-Marx C; Roland CL; Cleveland J; Oderda GM
J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):5-18. PubMed ID: 20345194
[TBL] [Abstract][Full Text] [Related]
34. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.
Chastek B; Korrer S; Nagar SP; Albers F; Yancey S; Ortega H; Forshag M; Dalal AA
J Manag Care Spec Pharm; 2016 Jul; 22(7):848-61. PubMed ID: 27348285
[TBL] [Abstract][Full Text] [Related]
35. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
Margolis J; Barron JJ; Grochulski WD
J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program.
Keast SL; Owora A; Nesser N; Farmer K
J Manag Care Spec Pharm; 2016 Apr; 22(4):347-56. PubMed ID: 27023688
[TBL] [Abstract][Full Text] [Related]
37. Increased health care costs associated with new persistent opioid use after major surgery in opioid-naive patients.
Brummett CM; Evans-Shields J; England C; Kong AM; Lew CR; Henriques C; Zimmerman NM; Sun EC
J Manag Care Spec Pharm; 2021 Jun; 27(6):760-771. PubMed ID: 33624534
[No Abstract] [Full Text] [Related]
38. Incremental Effect of the Addition of Prescriber Restrictions on a State Medicaid's Pharmacy-Only Patient Review and Restriction Program.
Keast SL; Pham T; Teel A; Nesser NJ
J Manag Care Spec Pharm; 2017 Aug; 23(8):875-883. PubMed ID: 28737989
[TBL] [Abstract][Full Text] [Related]
39. Estimating the Direct Costs of Outpatient Opioid Prescriptions: A Retrospective Analysis of Data from the Rhode Island Prescription Drug Monitoring Program.
Aroke H; Buchanan A; Wen X; Ragosta P; Koziol J; Kogut S
J Manag Care Spec Pharm; 2018 Mar; 24(3):214-224. PubMed ID: 29485950
[TBL] [Abstract][Full Text] [Related]
40. Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data.
Rice JB; Kirson NY; Shei A; Cummings AK; Bodnar K; Birnbaum HG; Ben-Joseph R
Appl Health Econ Health Policy; 2014 Aug; 12(4):435-46. PubMed ID: 24919646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
